Payment overview · 2025
General Payments
$2,847.21
112 reported records · 21 companies
Healthcare provider profile · identity verified
Marc James Comianos, DO
Allopathic & Osteopathic Physicians|Internal Medicine · LITTLE RIVER, SC · NPI 1013965532
Verified facts
What the public records show
CMS Open Payments records show Marc James Comianos, DO received $2,847.21 in general payments during 2025 across 112 reported records.
Amgen Inc. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Ubrelvy, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $464.39 | 16.3% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $438.72 | 15.4% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $263.93 | 9.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $211.48 | 7.4% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $191.98 | 6.7% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $186.41 | 6.5% | 16 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $182.27 | 6.4% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.54 | 6.3% | 12 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $140.04 | 4.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.63 | 4.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.28 | 2.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.18 | 2.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.88 | 2.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.91 | 2.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.62 | 1.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.28 | 1.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.32 | 1.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.16 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.95 | 0.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.91 | 0.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.33 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,847.21 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $350.94 | 11 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $263.93 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $221.61 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $200.61 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $199.32 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $187.71 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $182.27 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $155.32 | 11 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $140.04 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.63 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $123.82 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.83 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $74.31 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $72.94 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.28 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.18 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.88 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.91 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.59 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.87 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.72 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.62 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.09 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 211 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 137 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 186 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 172 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 104 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
186 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
172 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
211 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1313 | 371 |
| Amlodipine Besylate | Amlodipine Besylate | 841 | 258 |
| Losartan Potassium | Losartan Potassium | 689 | 206 |
| Levothyroxine Sodium | Levothyroxine Sodium | 661 | 185 |
| Lisinopril | Lisinopril | 613 | 175 |
| Omeprazole | Omeprazole | 565 | 162 |
| Pantoprazole Sodium | Pantoprazole Sodium | 484 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 432 | 132 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 122 |
| Gabapentin | Gabapentin | 405 | 115 |
| Trazodone Hcl | Trazodone Hcl | 369 | 117 |
| Metformin Hcl | Metformin Hcl | 363 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 327 | 94 |
| Montelukast Sodium | Montelukast Sodium | 322 | 114 |
| Tamsulosin Hcl | Tamsulosin Hcl | 299 | 93 |
| Azelastine Hcl | Azelastine Hcl | 276 | 161 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 265 | 94 |
| Buspirone Hcl | Buspirone Hcl | 264 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 262 | 69 |
| Prednisone | Prednisone | 258 | 147 |
| Pioglitazone Hcl | Pioglitazone Hcl | 252 | 72 |
| Tizanidine Hcl | Tizanidine Hcl | 249 | 99 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 243 | 186 |
| Ezetimibe | Ezetimibe | 242 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 237 | 66 |
| Furosemide | Furosemide | 235 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 231 | 65 |
| Metformin Hcl Er | Metformin Hcl | 230 | 61 |
| Simvastatin | Simvastatin | 229 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 224 | 67 |
| Allopurinol | Allopurinol | 214 | 60 |
| Eliquis | Apixaban | 211 | 50 |
| Azithromycin | Azithromycin | 209 | 139 |
| Famotidine | Famotidine | 203 | 74 |
| Glimepiride | Glimepiride | 202 | 50 |
| Carvedilol | Carvedilol | 200 | 59 |
| Meloxicam | Meloxicam | 196 | 60 |
| Mounjaro | Tirzepatide | 186 | 29 |
| Ozempic | Semaglutide | 172 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 51 |
| Sertraline Hcl | Sertraline Hcl | 160 | 37 |
| Potassium Chloride | Potassium Chloride | 158 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 146 | 40 |
| Jardiance | Empagliflozin | 137 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 116 | 92 |
| Doxycycline Hyclate | Doxycycline Hyclate | 114 | 90 |
| Celecoxib | Celecoxib | 113 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 25 |
| Donepezil Hcl | Donepezil Hcl | 99 | 30 |
| Finasteride | Finasteride | 98 | 34 |
| Atenolol | Atenolol | 97 | 28 |
| Spironolactone | Spironolactone | 94 | 26 |
| Alendronate Sodium | Alendronate Sodium | 91 | 27 |
| Doxepin Hcl | Doxepin Hcl | 91 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 39 |
| Synthroid | Levothyroxine Sodium | 88 | 24 |
| Clonidine Hcl | Clonidine Hcl | 87 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 87 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 23 |
| Bupropion Xl | Bupropion Hcl | 80 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 19 |
| Farxiga | Dapagliflozin Propanediol | 73 | 22 |
| Januvia | Sitagliptin Phosphate | 71 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 19 |
| Sucralfate | Sucralfate | 69 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 18 |
| Mirtazapine | Mirtazapine | 68 | 17 |
| Repatha Sureclick | Evolocumab | 63 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 15 |
| Valsartan | Valsartan | 59 | 17 |
| Amoxicillin | Amoxicillin | 57 | 39 |
| Lidocaine | Lidocaine | 57 | 25 |
| Glipizide | Glipizide | 55 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 17 |
| Warfarin Sodium | Warfarin Sodium | 54 | 12 |
| Valacyclovir | Valacyclovir Hcl | 53 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 13 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Lovastatin | Lovastatin | 48 | 16 |
| Colchicine | Colchicine | 47 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 17 |
| Fluconazole | Fluconazole | 46 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 19 |
| Meclizine Hcl | Meclizine Hcl | 46 | 27 |
| Estradiol | Estradiol | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 14 |
| Ibuprofen | Ibuprofen | 40 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 11 |
| Ramipril | Ramipril | 40 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 11 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 23 |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Naproxen | Naproxen | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 15 |
| Klor-Con M10 | Potassium Chloride | 26 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Desloratadine | Desloratadine | 22 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,847.21 · 112 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error